Here’s a bold statement: What if patients with low-risk atrial fibrillation (AF) could safely stop blood thinners after a successful ablation? This is the part most people miss—new research suggests it might be possible, but it’s not without controversy. The OCEAN trial, presented at the American Heart Association 2025 Scientific Sessions, reveals that low-risk patients treated with aspirin after successful AF ablation face no greater risk of stroke or other adverse outcomes compared to those on direct oral anticoagulants (DOACs) like rivaroxaban. But here’s where it gets controversial—should we really stop DOACs in these patients, and who qualifies as ‘low-risk’? Let’s dive in.
The OCEAN trial, involving 1,284 patients with a mean age of 66 and a CHA2DS2-VASc score of 1 or more, found strikingly low event rates in both treatment groups. After 36 months, the primary composite outcome of stroke, systemic embolism, or covert embolic stroke occurred in just 0.8% of rivaroxaban-treated patients and 1.4% of those on aspirin—a nonsignificant difference. Lead investigator Dr. Atul Verma suggests that patients with CHA2DS2-VASc scores of 1, 2, or even 3 might safely discontinue DOACs after successful ablation, but with a caveat: the trial excluded many patients with recent strokes, a high-risk subgroup. This is where opinions diverge—while some experts agree, others caution against broad application, fearing silent AF or delayed strokes.
The ALONE-AF study supports this idea, showing better outcomes when oral anticoagulation was stopped post-ablation. Yet, current guidelines still recommend long-term anticoagulation based on stroke risk, leaving clinicians in a tricky spot. Dr. Oussama Wazni emphasizes the need for honest patient conversations, recalling cases where even low-risk patients suffered strokes months later. Meanwhile, Dr. Christine Albert highlights the trial’s importance in providing risk-benefit data, suggesting that patients a year out from successful ablation with low-to-moderate stroke risk might not need DOACs.
But here’s the twist: the trial used aspirin as a comparator, which some now view as ineffective in reducing stroke risk in low-risk patients. This raises questions about whether aspirin acted more like a placebo, skewing results. Dr. Michael Ghannam warns against discontinuing anticoagulants in high-risk patients but acknowledges the trial’s value in sparking conversations about bleeding risks versus stroke prevention.
And this is the part most people miss—alternatives like apixaban, with lower bleeding risks, or left atrial appendage occlusion (LAAO) might offer safer options for those wary of stopping DOACs. Yet, the decision remains complex, balancing reversible bleeding risks against potentially devastating strokes.
So, what do you think? Is stopping DOACs post-ablation in low-risk patients a game-changer, or a risky gamble? Share your thoughts in the comments—let’s keep the debate alive!
